Extended-spectrum ¿-lactamase producing E.coli: An Overview

Abhishek Mehta

ISBN 10: 6203869570 / ISBN 13: 9786203869576

Published by LAP LAMBERT Academic Publishing Mai 2021, 2021

About this Item

Neuware -Extended-spectrum beta-lactamase (ESBL) producing strains pose the greatest therapeutic challenge and have been reported as an emerging pathogen causing life-threatening nosocomial infections. The developing countries bear the greatest burden of this problem and account for a major chunk of hospital-acquired infections. Failure to detect the ESBL producing bugs in the clinical treatment failures setup results in increased morbidity, mortality, complications, increased cost of treatment, and more important the outbreaks of highly resistant pathogens. These are more difficult to identify by routine laboratory assays, which can lead to a delay in diagnosis and institution of appropriate antimicrobial therapy. In this era of COVID, a significant number of deaths in hospitalized patients had been reported by secondary infections due to these MDR strains. This prompted me to expand my work in the form of a book. The Overview will definitely help Clinical microbiologists, infectious diseases consultants, students, and budding researchers, in understanding & tackling this problem. This will indirectly benefit the patients & the community as a whole.Books on Demand GmbH, Überseering 33, 22297 Hamburg 80 pp. Englisch.

Seller Inventory # 9786203869576

Bibliographic Details

• Title: Extended-spectrum ¿-lactamase producing E.coli: An Overview
• Publisher: LAP LAMBERT Academic Publishing Mai 2021
• Publication Date: 2021
• Language: English
• ISBN 10: 6203869570
• ISBN 13: 9786203869576
• Binding: Taschenbuch
• Condition: Neu
• Dimensions: 220W x 150H x 5D millimeters 220 millimeters width by 150 millimeters height by 5 millimeters depth
• Weight: 137 grams

About this title

Synopsis

Extended-spectrum beta-lactamase (ESBL) producing strains pose the greatest therapeutic challenge and have been reported as an emerging pathogen causing life-threatening nosocomial infections. The developing countries bear the greatest burden of this problem and account for a major chunk of hospital-acquired infections. Failure to detect the ESBL producing bugs in the clinical treatment failures setup results in increased morbidity, mortality, complications, increased cost of treatment, and more important the outbreaks of highly resistant pathogens. These are more difficult to identify by routine laboratory assays, which can lead to a delay in diagnosis and institution of appropriate antimicrobial therapy. In this era of COVID, a significant number of deaths in hospitalized patients had been reported by secondary infections due to these MDR strains. This prompted me to expand my work in the form of a book. The Overview will definitely help Clinical microbiologists, infectious diseases consultants, students, and budding researchers, in understanding & tackling this problem. This will indirectly benefit the patients & the community as a whole.<div><div style="text-align: justify;"><span>Extended-spectrum beta-lactamase (ESBL) producing strains pose the greatest therapeutic challenge and have been reported as an emerging pathogen causing life-threatening nosocomial infections. The developing countries bear the greatest burden of this problem and account for a major chunk of hospital-acquired infections. Failure to detect the ESBL producing bugs in the clinical treatment failures setup results in increased morbidity, mortality, complications, increased cost of treatment, and more important the outbreaks of highly resistant pathogens. These are more difficult to identify by routine laboratory assays, which can lead to a delay in diagnosis and institution of appropriate antimicrobial therapy. In this era of COVID, a significant number of deaths in hospitalized patients had been reported by secondary infections due to these MDR strains. This prompted me to expand my work in the form of a book. The Overview will definitely help Clinical microbiologists, infectious diseases consultants, students, and budding researchers, in understanding & tackling this problem. This&nbsp;will indirectly benefit the patients & the community as a whole.</span></div></div>